Advertisement

International Journal of Hematology

, Volume 80, Issue 3, pp 250–253 | Cite as

Successful Treatment with Cyclosporine and High-Dose Gamma Immunoglobulin for Persistent Parvovirus b19 Infection in a Patient with Refractory Autoimmune Hemolytic Anemia

  • Shigeki Ito
  • Tatsuo Oyake
  • Toshiyuki Uchiyama
  • Takeshi Sugawara
  • Kazunori Murai
  • Yoji Ishida
Case Report

Abstract

We describe a patient with persistent pure red cell aplasia due to human parvovirus B19 (HPVB19) infection during immunosuppressive therapy for refractory autoimmune hemolytic anemia (AIHA).The patient had been given corticosteroid (CS) and/or azathioprine for AIHA. During the course of treatment, reticulocyte count and hemoglobin levels decreased suddenly. Bone marrow aspirate showed erythroid lineage-specific aplasia with a few giant proerythroblasts, suggesting the presence of HPVB19 infection.The diagnosis of aplastic crisis due to HPVB19 infection was based on positive test results by polymerase chain reaction for HPVB19 immunoglobulin M (IgM) antibody and B19 DNA. Although splenectomy followed by administration of high-dose gamma globulin (HDIG) and plasma exchange were performed, the crisis and hemolysis recurred. Aplastic crises occurred several times when the B19 IgG result became negative and the CD4+ lymphocyte count was less than 300/εL. The patient showed complete recovery from anemia after CS was switched to cyclosporin A (CsA) and intermittent administration of HDIG. The result for B19 IgG antibody was continuously positive, and the DNA result became negative after these treatments.The results in this case indicated that concomitant administration of CsA and intermittent administration of HDIG can lead to cure of chronic anemia due to HPVB19 infection in patients with refractory AIHA.

Key words

Parvovirus B19 AIHA Cyclosporine Immunoglobulin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pattison JR, Jones SE, Hodgson J, et al. Parvovirus infections andhypoplastic crisis in sickle-cell anemia. Lancet. 1981;1:664–665.CrossRefGoogle Scholar
  2. 2.
    Lefrere JJ, Courouce AM, Bertrand Y, Girot R, Soulier JP. Human parvovirus and aplastic crisis in chronic hemolytic anemias: a study of 24 observations. Am J Hematol. 1986;23:271–275.CrossRefGoogle Scholar
  3. 3.
    Brown KE,Young NS. Parvovirus B19 in human disease. Ann Rev Med. 1997;48:59–67.CrossRefGoogle Scholar
  4. 4.
    Sahara N, Tamashima S, Ihara M. Hereditary spherocytosis associated with severe hypophosphatemia in patients recovering from aplastic crisis. Jpn J Clin Hematol. 1998;39:386–391.Google Scholar
  5. 5.
    Kurtzman GJ, Cohen B, Meyers P, et al. Persistent B19 parvovirus infection as a cause of severe anaemia in children with acute lymphocytic leukaemia. Lancet. 1988;2:1159–1162.CrossRefGoogle Scholar
  6. 6.
    Coulombel L, Morinet F, Mielot F, et al. Parvovirus infection, leukemia, and immunodeficiency. Lancet. 1989;1:101.CrossRefGoogle Scholar
  7. 7.
    Corral D, Darras F, Jensen C, et al. Parvovirus B19 infection causing pure red cell aplasia in a recipient of pediatric donor kidneys. Transplantation. 1993;55:427–430.CrossRefGoogle Scholar
  8. 8.
    Nour B, Green M, Michaels M, et al. Parvovirus B19 in pediatric transplant patients. Transplantation. 1993;55:835–838.CrossRefGoogle Scholar
  9. 9.
    Galor A, O’Brien T. Rituximab treatment for relapsed autoimmune hemolytic anemia in Evans syndrome. Int J Hematol. 2003;78:335–336.CrossRefGoogle Scholar
  10. 10.
    Dunder S, Ozdemir O, Ozcebe O. Cyclosporine in steroid-resistant auto-immune haemolytic anemia. Acta Haemotol. 1991;86:200–202.CrossRefGoogle Scholar
  11. 11.
    Rackoff WR, Manno CS. Treatment of refractory Evans syndrome with alternate-day cyclosporine and predonisone. Am J Pediatr Hematol Oncol. 1994;16:156–159.PubMedGoogle Scholar
  12. 12.
    Tsudo M, Moriguchi T. Effective cyclosporine therapy to resistant Evans syndrome. Jpn J Clin Hematol. 1996;37:1289–1292.Google Scholar
  13. 13.
    Yocum DE, Wilder RL, Dougherty S, Klippel JH, Pillemer S, Wahl S. Immunological parameters of response in patients with rheumatoid arthritis treated with cyclosporine A. Arthritis Rheum. 1990;33:1310–1316.CrossRefGoogle Scholar
  14. 14.
    Yocum DE, Nordensson K, Gaithers L. Combination cyclosporine (CsA) plus methotrexate (MTX): immunologic effects over 18 onths of therapy. Arthritis Rheum. 1997;40(suppl 9):S193.Google Scholar
  15. 15.
    Frickhofen N, Abkowitz J, Safford M, et al. Persistent parvovirus infection in patients infected with human immunodeficiency virus type 1(HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med. 1990;113:926.CrossRefGoogle Scholar
  16. 16.
    Young NS. Parvovirus infection and its treatment. Clin Exp Immunol. 1996;104:26–30.PubMedGoogle Scholar
  17. 17.
    Koduri PR, Kumapley R, Valladares J, Teter C. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin: a report of eight patients. Am J Hematol. 1999;61:16–20.CrossRefGoogle Scholar
  18. 18.
    Prowse C, Ludlam CA,Ysap PL. Human parvovirus B19 and blood products. Vox Sang. 1997;72:1–10.CrossRefGoogle Scholar
  19. 19.
    Hayakawa F, Imada K, Towatari M, Saito H. Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol. 2002;118:1187–1189.CrossRefGoogle Scholar
  20. 20.
    Wong TY, Chan PK, Leung CB, Szeto CC, Tam JS, Li PK. Parvovirus B19 infection causing red cell aplasia in renal transplantation on tacrolimus. Am J Kidney Dis. 1999;34:1132–1136.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2004

Authors and Affiliations

  • Shigeki Ito
    • 1
  • Tatsuo Oyake
    • 1
  • Toshiyuki Uchiyama
    • 1
  • Takeshi Sugawara
    • 1
  • Kazunori Murai
    • 1
  • Yoji Ishida
    • 1
  1. 1.Department of Hematology/OncologyIwate Medical University School of MedicineMorioka, IwateJapan

Personalised recommendations